The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. [electronic resource]
Producer: 20180223Description: 81172-81186 p. digitalISSN:- 1949-2553
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Apoptosis Regulatory Proteins -- metabolism
- Boron Compounds -- pharmacology
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Female
- Glycine -- analogs & derivatives
- Humans
- Interferon alpha-2
- Interferon-alpha -- pharmacology
- Melanoma -- drug therapy
- Mice, Inbred BALB C
- Mice, Nude
- Mutation
- Proteasome Endopeptidase Complex -- drug effects
- Proteasome Inhibitors -- pharmacology
- Proto-Oncogene Proteins B-raf -- genetics
- Recombinant Proteins -- pharmacology
- Skin Neoplasms -- drug therapy
- Time Factors
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.